NUCLEOTIDE DERIVATIVES WHICH ARE HCV INHIBITORS FOR USE IN THE TREATMENT OF HEPATITIS C

NUCLEOTIDE DERIVATIVES WHICH ARE HCV INHIBITORS FOR USE IN THE TREATMENT OF HEPATITIS C

Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir; or b)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: TARGETT-ADAMS, PAUL, TORSSELL, STAFFAN, KALAYANOV, GENNADIY, PINHO, PEDRO
Format: Patent
Sprache:chi ; eng
Schlagworte:
CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SUGARS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir; or b) simeprevir and/or JNJ56914845; or c) an HCV protease inhibitor selected from paritaprevir or ABT493, and an NS5A inhibitor selected from ombitasvir or ABT-530; or d) alisporavir; or e) EDP-239; or f) odalasvir and/or sovaprevir; or g) grazoprevir and/or elbasvir.